Embryos produced by assisted reproductive technologies are commonly associated with a high level of aneuploidy. Currently, 24-chromosome profiling of embryo biopsy samples by arraybased methods is available to identify euploid embryos for transfer that have a higher potential for implantation and development to term. From a laboratory and patient perspective, there is a need to explore the feasibility of developing an alternative method for routine aneuploidy assessment of embryos that would be more comprehensive, cost-effective, and efficient. We speculated that aneuploidy could be readily assessed in test single-cell biopsy samples by first performing whole genome amplification followed by library generation, massively parallel shot-gun sequencing, and finally bioinformatics analysis to quantitatively compare the ratio of uniquely mapped reads to reference cells. Using Down syndrome as an example, the copy number change for chromosome 21 was consistently 1.5-fold higher in multiple cell and single-cell samples with a 47,XX,+21 karyotype. Applying the validated sequencing strategy to 10 sister blastomeres from a single human embryo, we showed that the aneuploidy status called by sequencing was consistent with short tandem repeat allelic profiling. These validation studies indicate that aneuploidy detection using sequencing-based methodology is feasible for further improving the practice of preimplantation genetic diagnosis.
INTRODUCTION
Chromosomal aneuploidy in embryos originating from meiotic and mitotic errors commonly results in failed assisted reproduction. Historically, aneuploidy screening of preimplantation embryos generated by assisted reproductive technologies has been performed by single-cell fluorescence in situ hybridization (FISH) analysis of five to twelve chromosomes [1, 2] using biopsied embryonic material such as polar bodies, blastomeres, or trophectoderm cells. However, following FISH, 25%-38% of embryos transferred to patients were still aneuploid for chromosomes not probed by FISH [3] . More recently, other methods such as array comparative genomic hybridization (CGH) [4] , single nucleotide polymorphism (SNP) arrays [5] , and quantitative fluorescent PCR [6] have been developed for single-cell analysis and applied to in vitro fertilized (IVF) embryo biopsies to give information on the aneuploidy status of all the chromosomes. Current data suggests that the combination of blastocyst biopsy and array analysis for identifying euploid embryos for transfer is beginning to provide improved benefits to infertile patients in terms of higher implantation and live birth rates [7, 8] . Whilst large randomized control trials to validate these observations have yet to be published, a pilot randomized control study of good-quality blastocysts showed significantly higher implantation and pregnancy rates after array CGH was applied to select single euploid embryos for transfer [5] .
The advent of next-generation sequencing provides unprecedented opportunities in the field of reproductive medicine, including preimplantation genetic diagnosis (PGD) [9] [10] [11] . Central to designing a robust single-cell sequencing strategy is the whole genome amplification (WGA) step that is critical to providing sufficient DNA template for downstream library construction and sequencing. While most available WGA methods produce high yields of DNA, none have the capacity to cover all the sequences of the genome in a single cell, and amplification bias due to GC content, allelic dropout, and preferential allelic amplification remain the most significant limitations [12] [13] [14] . Nonetheless, emerging data suggests that the genomic regions amplified by multiple displacement amplification are generally very consistent from one single cell to another [15] . Accordingly, we applied the multiple displacement amplification-based Repli-G WGA system that produces 20-30 kb genomic DNA fragments and used the amplified DNA template for construction of sequencing libraries with an average insert size of ;300 bp. To further normalize WGA coverage for accurate single-cell aneuploidy detection, we then compared the proportion of chromosomal sequences generated in the test cell with those generated in a panel of reference single cells as previously described [16] , allowing calculation of chromosome copy number (CN) in the test cell. In this study, we developed and validated a molecular pipeline from a single cell to a sequencing karyotype (Fig. 1) , showed that the method was accurate for aneuploidy diagnosis in single lymphocytes, and reported a complete aneuploidy assessment of a human embryo by sequencing.
Peripheral blood samples were collected for routine prenatal diagnosis at the Chinese PLA General Hospital, Beijing, China. Karyotyping by Giemsa staining and G banding confirmed the karyotypes of the cell lines 46,XX, 46,XY, and 47,XY,þ21 used in the study. Genomic DNA was prepared using the DNA Easy Blood and Tissue Kit (Qiagen) and quantitated by Nanodrop (Thermo Scientific). Low template genomic DNA samples for WGA were obtained from defined numbers of patient's lymphocytes. Isolated lymphocytes were first washed three times with PBS buffer, and the desired cell number were collected by microscopy and micromanipulation into a final volume of 4 ll of PBS buffer in a 200 ll PCR tube. PGD was performed at the Tangdu Hospital IVF Center, Fourth Military Medical University, Xi'an, China. The practice of PGD and human embryo research was approved by the Ethics Committee of Tangdu Hospital, and all the protocols followed the ethical guidelines of this committee. Informed written consent was provided by all patients prior to commencement of IVF and PGD. Cleavage-stage embryos from IVF/PGD cycles were screened at Day 3 postfertilization for chromosome abnormalities by FISH [17] to identify euploid embryos for transfer. For embryo biopsy, a Saturn Laser System (Research Instruments) was used to create a slit in the zona pellucida. Biopsy of individual blastomeres was performed by micromanipulation using a blunt flame-polished biopsy pipette with an inner diameter of 30-50 lm. One or two euploid embryos were transferred to the patient, and the remaining embryos from the cohort were frozen as part of routine clinical practice.
Whole Genome Amplification and DNA Sequencing
Specific single cells or defined numbers of cells were subjected to WGA with RE-PLI-g Mini Kit (QIAGEN, Inc.) according to the instructions of the manufacturer along with a no-cell reaction serving as the negative control. The DNA concentration of the WGA products was measured by Nanodrop. A total of 100 ng of the WGA DNA product was treated with fragmentation buffer to produce ;300 bp fragments, and then primer tagged sequencing libraries were generated using additional reagents from the Nextera DNA Sample Preparation Kit (Illumina, Inc.). DNA libraries were subjected to deep sequencing on the HiSeq2000 platform (Illumina, Inc.), and approximately 8 million single-end 36 bp reads were obtained per sample. All the sequencing reads were aligned to the human genome sequence (hg19) using the Burrows-Wheeler aligner mapping algorithm [18] and their chromosomal origins identified. Only the uniquely aligned reads were used for data analysis. An Excel file summarizing the complete sequencing data for all the samples analyzed in the study is available on request.
Data Analysis
For each chromosome, the chromosome representation (CR) value and GC% were calculated according to following equations: CR ¼ (count of the reads uniquely mapped to the chromosome of interest)/(total count of the reads uniquely mapped to all the autosomal chromosomes) and GC% ¼ (count of G and C in the reads uniquely mapped to the chromosome of interest)/(total count of A, C, G, and T bases in the reads uniquely mapped to the given chromosome of interest). Because there is a linear relationship between GC% of reads mapped to each chromosome and reads percentage of each chromosome on the Illumina sequencing system for unamplified genomic DNA, GC correction was used to reduce the sequencing variation for CN analysis [16] . Chromosome CN change for any chromosome in the test sample was defined as (CR test value)/ (mean CR reference value). Because theoretical CR values of 0.5, 1.0, and 1.5 represent one, two, and three chromosomal copies, respectively, we applied standard cut-off thresholds of 0.75 and 1.25 to indicate monosomy and trisomy, respectively, as previously described [19] .
Short Tandem Repeat Analysis for Confirmation of Sequencing Karyotypes
Polymorphic short tandem repeat (STR) markers for chromosomes 1, 19, 21, 22, and X previously used for aneuploidy diagnosis of translocations [20] were selected to confirm blastomere aneuploidies. Criteria for STR marker selection included either a tri-or tetranucleotide repeat sequence to avoid PCR stutter artifact, a heterozygosity index .0.7, and a broad allelic range (.6 known alleles). Fluorescent primer sequences used for each marker were those previously published [20] or a redesign to maximize specificity and sensitivity. Forward primers were labeled with either 6-FAM, HEX, or TETRA (all from Takara Biotechnology). Fluorescent PCR reactions were performed in 25 ll of AmpliTaq Gold 360 master mix containing 20 ng of WGA DNA and 20 lM of each primer. PCR cycling was performed at 958C for 10 min, then for 15 cycles 
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at 948C for 30 sec, 638C for 60 sec with touchdown 0.58C per cycle, 728C for 60 sec, and finally for 24 cycles at 948C for 30 sec, 568C for 60 sec, and 728C for 60 sec with a final cycle of 728C for 5 min. PCR products were electrophoresed on 1.5% ethidium bromide agarose gels to verify the amount and expected size of the PCR products. Products were diluted in formamide containing GeneScan 500 ROX labeled molecular weight standards and then electrophoresed on an ABI 3730XL Genetic Analyzer (Applied Biosystems), and allelic sizes were assigned using GeneScan software.
RESULTS

Determination of Trisomy 21 in Low Template DNA
A reference set of 46,XX 200 ng DNA samples (n ¼ 15) were initially sequenced according to the established protocol ( Fig. 1) , and the mean CR values were calculated for each chromosome (data not shown). All the observed CR values were similar to expected theoretical CR values calculated from the known chromosomal physical sizes predicted from the hg19 reference genome, indicating that the observed CR values for disomic chromosomes were approximately proportional to the physical size of each chromosome. This suggested that there was a uniform spread of the ;5 million uniquely mapped sequencing reads across all the chromosomes. Taken together, the reference DNA analyses provided a robust starting point for confidently identifying aneuploidy because an approximately 0.5-or 1.5-fold shift in CR value of test compared to reference for any chromosome would represent chromosomal loss (monosomy) or chromosomal gain (trisomy), respectively. As an aneuploidy example, we modeled Down syndrome diagnosis by comparing the sequencing results of a low template 47,XY,þ21 DNA sample to those of an equivalent reference 46,XY DNA sample. Sequencing analysis of a 46,XY,þ21 200 ng DNA sample showed no significant CN change compared to reference for the expected disomic chromosomes, but an ;1.5 CN change for chromosome 21, indicative of trisomy (Fig. 2, representative chromosomes 1,  14, 21 , X, and Y). To determine if trisomy 21 prediction remained robust using much lower amounts of input template DNA and thus requiring a preamplification WGA step, sequencing was repeated using decreasing amounts of input genomic DNA at 330, 132, 66, and 6.6 pg, equivalent to decreasing numbers of lymphocytes (n ¼ 50, 20, 10, and 1, respectively). In general, as the concentration of input genomic DNA was decreased to as low as 6.6 pg, the CN values for each expected disomic chromosome were similar to the reference, but for chromosome 21, the CN was ;1.5-fold higher. On the basis of these findings, we concluded that any genome bias introduced by the WGA step was relatively consistent from sample to sample, thus allowing normalization of the test and reference sequencing data sets to determine the correct ploidy. Importantly, diagnosis of trisomy 21, as well as disomy, remained true even down to the single-cell level.
Determination of Trisomy 21 in Single Cells
The sequencing strategy for determination of trisomy 21 was more rigorously tested at the single-cell level by comparing reference lymphocyte samples 46,XX (n ¼ 18 cells) and 46,XY (n ¼ 17 cells) with test samples 47,XY,þ21 (n ¼ 14 cells). CR plots for representative chromosomes 1, 14, 21, X, and Y are shown in Figure 3 . Consistent with the low template DNA results, there was no significant difference in CN for the expected disomic chromosomes in the 47,XY,þ21 cells compared to mean reference values for the 35 lymphocytes with a normal karyotype, whereas for chromosome 21, the CN was again ;1.5-fold higher (mean 1.58) in all 14 cells. The X chromosome had a consistent CR value of ;0.5 (mean 0.48) whereas the CR value for Y fluctuated more widely from 0.5 (mean 0.82). This artificial increase in CN for the Y chromosome is known to be caused by a significantly higher content of repetitive sequences [21] . Furthermore, the 99% confidence intervals (CIs) for all expected disomic chromosomes, the X chromosome and chromosome 21 were narrow (range for all chromosomes of 0.015-0.078) and when applied to the mean, did not exceed the threshold limits set for disomy (.0.75 and ,1.25), monosomy (,0.75) and trisomy (.1.25), respectively (Fig. 3) . Thus, on the basis of these chromosome CN analyses, trisomy 21 and male gender was reliably and accurately determined in all the 47,XX,þ21 single-cell samples by our sequencing strategy.
Aneuploidy Analysis of Individual Blastomeres from a Human IVF Embryo
As proof of principle for PGD, we further applied this sequencing strategy for aneuploidy assessment to an in vitro fertilized embryo that was originally diagnosed as female (XX) by FISH analysis of two biopsied blastomeres (Supplemental Fig. S1 ; Supplemental Data are available online at www. biolreprod.org). The embryo, however, was developmentally abnormal with the presence of 12 blastomeres at cleavage stage, and the patient later consented to donate the biopsied ANEUPLOIDY ASSESSMENT OF IVF EMBRYOS BY SEQUENCING embryo for aneuploidy research. The frozen embryo was thawed, and the remaining 10 sister blastomeres in the biopsied embryo were subsequently isolated and subjected to WGA and sequencing to determine chromosomal CN change using the 35 normal lymphocytes as reference. Based on CN analysis, blastomeres 3 and 5 were assigned a 48,XX,þ19 þ22 karyotype, blastomeres 4 and 9 were assigned a 45,XX,-1 karyotype, and blastomeres 6, 7, 8, 10, 11, and 12 were assigned normal 46,XX karyotypes (Fig. 4A , representative blastomeres 3, 4, and 12, and Supplemental Fig. S2 , all the chromosome CN profiles for the remaining blastomeres). Similar to the population CR value fluctuations for individual chromosomes in single lymphocytes, we also observed similar chromosomal CR value fluctuations in the 10 blastomeres, but with slightly wider 99% CIs (0.026-0.197). Based on very similar duplicate sequencing results for blastomere 8 (Supplemental Fig. S2 ), we speculated that the slightly wider 99% CIs for CR values in the embryonic blastomeres compared to single lymphocytes was due to a lower quality WGA product, possibly caused by DNA fragmentation, a phenomenon known to be associated with embryos subjected to a frozen/thaw cycle followed by short-term culture and micromanipulation [22] .
To confirm these sister blastomere karyotypes assigned by sequencing, we analyzed the original matching WGA products by fluorescent PCR, specifically targeting three highly polymorphic STR markers for each of the aneuploid chromosomes 1, 19, and 22 as well as chromosomal X STR markers for embryo gender and chromosome 21 STR markers as a disomic chromosome control (Fig. 4B) . For blastomeres 6, 7, 8, 10, 11, and 12 (representative blastomere12), chromosomes 1, 19, and 22 were confirmed as disomic by at least one STR marker showing a diallelic pattern (;1:1 allelic ratios). Monosomy chromosome 1 assigned to blastomeres 4 and 9 was confirmed by a consistent monoallelic STR pattern. Trisomy 19 and 22 assigned to blastomeres 3 and 5 was confirmed by a 1:.5 allelic ratio of at least one STR marker indicative of a double-dose diallelic pattern of trisomy. In all the blastomeres, disomy of the control chromosome 21 and the X chromosome was also confirmed by at least one STR marker showing a diallelic pattern. The gender diagnosis of female (XX) for each blastomere was further confirmed by the presence of an AMELX gene (Fig. 4B) and the absence of a Yspecific SRY gene (Supplemental Fig. S1 ), which was consistent with the original FISH diagnosis of XX for the two biopsied blastomeres. Taken together, the assigned sequencing karyotypes for each sister blastomere were concordant with STR profiling.
DISCUSSION
In this study, we developed and validated a sequencing protocol that is capable of predicting chromosomal aneuploidies in single cells and demonstrated the potential clinical utility of the method by performing a total chromosome aneuploidy assessment of a single human embryo. This singlecell sequencing strategy offers a new approach to aneuploidy assessment of either polar bodies, blastomeres, or trophectoderm biopsy samples, and therefore is compatible with the current embryology practices of individual PGD laboratories. In addition, the method offers several advantages over current array-based methods. Firstly, the procedure from embryo biopsy to a sequencing karyotype can be potentially performed in under 16 h, thus, providing the patient with rapid results. Secondly, with the option of high throughput multiplexing of sequencing samples in the same flow cell, the procedure is efficient, scalable and cost-effective. Thirdly, the molecular pipeline from embryo biopsy to sequencing karyotype has minimal processing steps and sample tube transfers, and combined with internal sample sequence barcoding during library construction, can potentially reduce the incidence of misdiagnosis through human error in a busy laboratory environment. Notwithstanding, due to the requirement of expensive next-generation sequencing platforms and sophisticated bioinformatics algorithms to analyze large complex data sets, this new technology is probably best delivered in the short term by more well-established PGD laboratories that can additionally outsource their sequencing service to other smaller IVF clinics using a transport PGD model.
Our study provided a complete aneuploidy assessment of a human embryo by sequencing. We found the presence of three separate cell lines in embryo; namely, 46XX, 48XX,þ19,þ22, and 45XX,-1 indicating that the embryo developed as a diploid/ aneuploid mosaic. The double-dose diallelic STR profile of chromosomes 19 and 22 in one cell line suggested that both trisomies arose by mitotic errors during the later cleavage-stage divisions. Similarly, the presence of monosomy 1 in another two sister blastomeres also suggested that this error arose in the same cleavage division. Cleavage-stage embryos with chro- WANG ET AL. mosomal mosaicism generated by mitotic errors, such as the one described here, have been commonly observed in embryo cohorts of infertile patients with a poor prognosis for pregnancy [23] and presents a difficult clinical conundrum because the diagnosis can be either euploid or aneuploidy, depending on which blastomere is biopsied. Recent analysis of normally developing cleavage-stage embryos by array CGH showed that 70% exhibited some degree of chromosomal mosaicism [24] . Many of these mosaic embryos, particularly those with a significantly high proportion of aneuploidy blastomeres are probably not viable, and thus when transferred as part of a multiple embryo transfer, they potentially reduce the benefit of PGD for many patients. Our findings of chromosomal mosaicism amongst the embryonic blastomeres in this research embryo further highlights the potential pitfalls of performing embryo biopsy and PGD at the cleavage stage of development and advocates for blastocyst biopsy, where levels of chromosomal mosaicism are lower in the trophectoderm cells and the chromosomal constitution of the trophectoderm closely resembles that of the pluripotent inner cell mass cells that form the fetus [25] .
Recently, a SNP-based single-cell sequencing strategy combined with much deeper sequencing was successfully applied to oocyte polar body biopsy samples, enabling the determination of aneuploidy in the corresponding oocytes [26] . In addition, the bioinformatics algorithms applied to the polar body SNP data also displayed sufficient resolving power for potentially detecting CN variation (CNV) down to the megabase level. Similarly, the new single-cell massively parallel shotgun sequencing method we describe here also 
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has the capacity through bioinformatics to be developed further to achieve a much higher resolution CNV analysis of embryo biopsy samples by compartmentalizing the mapped sequencing reads of the whole chromosomes to successive sequencing bins along the length of each chromosome and then analyzing the ratio of test to reference reads for each sequencing bin. By this approach, high resolution CNV detection similar to the SNPbased method [26] could be similarly achieved without the need and cost of deeper sequencing. In conclusion, based on the results of this study and several recent studies [11, 26] , there is no doubt that next-generation sequencing methodologies will play a key role in expanding the scope of embryo genetic analyses to include submicroscopic duplication and microdeletion and syndromes and, additionally, monogenic diseases by more targeted single gene approaches [9] . However, on a cautionary note, before any next-generation sequencing technology is implemented into clinical PGD practice, it will be essential to perform well-designed validation studies against current technologies such as array CGH and SNP arrays using the same embryo biopsy WGA products as template.
